P2Y12 receptor inhibitors for secondary prevention of ischemic stroke

Fang Liu, Udaya S. Tantry, Paul A. Gurbel

Research output: Contribution to journalReview articlepeer-review


Introduction: Ischemic stroke (IS) is a major cause of death and disability worldwide. The P2Y12 receptor plays a critical role in the formation of a stable thrombus leading to ischemic complications. Therefore, P2Y12 receptor inhibitors constitute a major antiplatelet strategy in the secondary prevention of IS.Areas covered: We searched articles about P2Y12 receptor inhibitors and stroke in PubMed published until December 2014. This is a comprehensive review of the role of P2Y12 receptor inhibitors alone and in combination with aspirin in the secondary prevention of noncardioembolic stroke.Expert opinion: The potential benefit of more potent antiplatelet therapy for secondary stroke prevention must be weighed against the risk of bleeding in patients with IS. Short-term (≤ 3 months) dual antiplatelet therapy with clopidogrel and aspirin that is initiated early after IS or transient ischemic attack due to large artery atherosclerosis appears most efficient.

Original languageEnglish (US)
Pages (from-to)1149-1165
Number of pages17
JournalExpert opinion on pharmacotherapy
Issue number8
StatePublished - Jun 1 2015


  • Clopidogrel
  • P2Y receptor inhibitor
  • Prasugrel
  • Stroke
  • Ticagrelor
  • Ticlopidine

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'P2Y12 receptor inhibitors for secondary prevention of ischemic stroke'. Together they form a unique fingerprint.

Cite this